MVP: A New Treatment for Advanced Breast Cancer
Author Information
Author(s): A Urruticoechea, C D Archer, L A Assersohn, R K Gregory, M Verrill, R Mendes, G Walsh, I E Smith, S R D Johnston
Primary Institution: Royal Marsden NHS Trust
Hypothesis
This study assesses the efficacy and tolerability of a combination of mitomycin C, vinblastine, and cisplatin in patients with metastatic breast cancer previously treated with chemotherapy.
Conclusion
The MVP regimen is an effective and well-tolerated treatment for patients with metastatic breast cancer, even those heavily pretreated.
Supporting Evidence
- 87 patients with metastatic breast cancer were treated with the MVP regimen.
- The overall response rate was 32%, with 31% showing partial response and 1% complete response.
- Stable disease was observed in 21% of patients.
- The treatment was well-tolerated with mild toxicity.
- Median progression-free survival was 4 months and overall survival was 8 months.
Takeaway
Doctors tested a new medicine for women with advanced breast cancer, and it worked well and was safe to use.
Methodology
This phase II study involved treating 87 patients with a specific chemotherapy regimen and assessing their responses and side effects.
Limitations
The study was limited to patients who had previously received chemotherapy, which may affect the generalizability of the results.
Participant Demographics
The study included 87 women with metastatic breast cancer, most of whom had previously been treated with anthracyclines and taxanes.
Statistical Information
Confidence Interval
95% CI: 22–42%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website